Professor Michael Hallek is the Director for the Department of Internal Medicine I at the University of Cologne and the Director of the Center of Integrated Oncology CIO Aachen, Bonn, Düsseldorf and Cologne, Germany.
Professor Hallek gained his medical degree from the University of Munich in 1985 and was a Research Associate at the Dana Farber Cancer Institute and Harvard Medical School from 1990–1992. He became a senior consultant at the University of Munich between 1995–2003.
His main research focus is chronic lymphocytic leukemia (CLL), with the long-term interest to study oncogenic signaling events. In 1996, he founded the German CLL Study Group and is its chairman until today.
Positions of responsibility/awards:
- Strategy Advisory Board “National Decade against Cancer”, Federal Ministry of Education and Research, since 2019
- President, Walter-Siegenthaler Society, since 2019
- Awarded the Ham-Wasserman Lecture, American Society of Hematology (2018)
- Awarded the Johann-Georg-Zimmermann Award (2018)
- Chairman Scientific Committee, European School of Hematology, Paris, since 2018
- Awarded the German Cancer Award and the Arthur Burkhardt Award (2017)
- Awarded the Walter-Siegenthaler Medal (2016)
- Executive Chairman, German Society of Hematology and Oncology (DGHO) since 2018
- On the scientific board of the German Chamber of Physicians (Bundesärztekammer)
- Editor-in-Chief of Oncology and Research Treatment
- Member of the National Academy of Sciences Leopoldina
- Chairman of the Clinical Research Unit 286 “DNA damage response in CLL” (DFG)
- Binet-Rai Medal of the International Workshop on CLL (iwCLL; 2013)
- Awarded the Paul Martini Prize (2012)
- Scientific Committee (Core Group) iwCLL (2000)
- Research Group Leader, Gene Center Munich (1994–2005)
- In 1996, he founded the German CLL Study Group and acts as chairman